Explore our
BioLizard wins best poster award at the European Society for Spatial Biology Conference
BioLizard is proud to have received the Best Poster Award at the European Society for Spatial Biology (ESSB) conference, recognising our work on benchmarking cell segmentation methods for single-cell spatial transcriptomics.
Paul Vauterin Moves from CTO to COO at BioLizard
Paul Vauterin has transitioned from Chief Technology Officer (CTO) to Chief Operating Officer (COO) at BioLizard, reflecting a shift in focus towards helping organisations integrate AI into their operations and unlock greater value from their data.
BioLizard Wins 2025 BioTech Breakthrough Award For “Bioinformatics Innovation of the Year”
BioLizard has been named “Bioinformatics Innovation of the Year” in the 2025 BioTech Breakthrough Awards. The honor spotlights Bio|Verse® Navigator, a visual analytics workspace that unifies complex R&D data so scientists can decide faster, with confidence.
Industry leader and multi-omics pioneer joins leadership team to advance AI-driven solutions
BioLizard has appointed Dr. Alexander Scheer as Chief Scientific Officer, adding 25+ years of translational R&D leadership across biotech and pharma. He will help scale BioLizard’s multi-omics and AI-driven strategy, strengthening work in biomarkers, precision medicine, and therapeutic innovation.
The Vlerick Venture Award 2025 goes to Liesbeth Ceelen
Jos De Vuyst and Liesbeth Ceelen are the winners of the 2025 Vlerick Awards, recognizing outstanding leadership and entrepreneurship.
BioLizard Logs Stellar First Half of 2025: Growth, Innovation & Recognition
BioLizard’s first half of 2025 shows strong growth, AI innovation, and global recognition with new grants, leadership, and major industry awards.
BioLizard Awarded Grant from VLAIO to Advance AI-Powered Biomedical Solution for Accelerated Drug Development
VLAIO has awarded BioLizard a grant to advance its AI-driven Bio|Verse® platform. The new application will use large language models to rapidly extract and structure insights from vast biomedical datasets, empowering faster, smarter drug discovery.
BioLizard has been listed as a Trends Gazelle
BioLizard named a Trends Gazelle 2025! Recognized among Belgium’s fastest-growing companies for exceptional growth, innovation, and impact in life sciences — a true testament to the power of our team and data-driven mission.
BioLizard Launches Bio|Verse® Navigator for Easy Exploration of Complex Biomedical Data
BioLizard unveils Bio|Verse® Navigator, an advanced visual analytics platform empowering scientists to explore and interpret complex biomedical data in real time. The AI-native tool accelerates discovery across biotech, pharma, and healthcare research.
BioLizard announces the appointment of Caroline Vanovermeire as Chair of the Board
BioLizard appoints Caroline Vanovermeire as Chair of the Board, succeeding André van de Sande. Caroline brings extensive leadership experience to guide BioLizard’s growth and innovation in bioinformatics, data analytics, and life sciences consulting.